Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agilon Health (AGL) Cash & Equivalents (2020 - 2025)

Agilon Health (AGL) has disclosed Cash & Equivalents for 6 consecutive years, with $173.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 7.71% year-over-year to $173.7 million, compared with a TTM value of $173.7 million through Dec 2025, down 7.71%, and an annual FY2025 reading of $173.7 million, down 7.71% over the prior year.
  • Cash & Equivalents was $173.7 million for Q4 2025 at Agilon Health, up from $171.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.1 billion in Q2 2021 and bottomed at $105.3 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $470.4 million, with a median of $292.6 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents surged 873.86% in 2021, then tumbled 76.88% in 2023.
  • Year by year, Cash & Equivalents stood at $1.0 billion in 2021, then crashed by 55.26% to $465.3 million in 2022, then crashed by 76.88% to $107.6 million in 2023, then soared by 74.98% to $188.2 million in 2024, then dropped by 7.71% to $173.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for AGL at $173.7 million in Q4 2025, $171.4 million in Q2 2025, and $188.2 million in Q4 2024.